Articles related to VISION LOSS

A systematic review and meta-analysis linked plasma exchange with high recovery rates in MOGAD attacks, especially optic neuritis. Included studies were observational and could not isolate PLEX effects.

A Swedish register-based cohort associated GLP-1 receptor agonist use with higher relative risk of anterior ischemic optic neuropathy. Absolute event rates were low, and findings attenuated after diabetes-severity controls.

University of Oklahoma researchers identified a photoreceptor lysosomal recycling pathway regulated by PIKfyve. Mouse-model disruption produced photoreceptor degeneration and RPE changes resembling macular degeneration biology.

Ocular Therapeutix announced FDA alignment on a planned fourth-quarter 2026 NDA submission for Axpaxli in wet AMD, based on SOL-1 phase 3 efficacy data and interim safety results from the ongoing SOL-R trial.

AREDS2 remains the evidence-based standard for AMD supplementation, but expanding understanding of complement dysregulation, mitochondrial dysfunction, and macular carotenoid biology has prompted discussion about whether a next-generation formulation could address pathways the current one does not target.

Primary trabeculectomy reduced the rate of visual field loss by approximately 50% compared with a medications-first approach in newly diagnosed advanced open-angle glaucoma patients across a 5-year randomized trial, though standard quality-of-life instruments failed to detect that clinical benefit.